Clinical use of proteasome inhibitors in the treatment of multiple myeloma

Pharmaceuticals

Volumn 8, Issue 1, 2014, Pages

  Merin, Noah M ^a   Kelly, Kevin R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Multiple myeloma; Proteasome inhibitors; Toxicity

Indexed keywords

BENDAMUSTINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DELANZOMIB; DEXAMETHASONE; FILANESIB; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE INHIBITOR; IBRUTINIB; IXAZOMIB; LENALIDOMIDE; MELPHALAN; MUCIN 1; OPROZOMIB; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SELINEXOR; VORINOSTAT;

ANOREXIA; APOPTOSIS; CANCER INHIBITION; COGNITIVE DEFECT; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG USE; DYSPNEA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; FATIGUE; GENE EXPRESSION; HALLUCINATION; HEADACHE; HEART FAILURE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPONATREMIA; HYPOPHOSPHATEMIA; IC50; INFECTION PREVENTION; INFUSION RELATED REACTION; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; THORAX PAIN; TREATMENT OUTCOME; UPREGULATION; VIRUS REACTIVATION; VOMITING;

EID: 84923066600     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph8010001     Document Type: Review

References (95)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
2. Siegel, R.; DeSantis, C.; Virgo, K.; Stein, K.; Mariotto, A.; Smith, T.; Cooper, D.; Gansler, T.; Lerro, C.; Fedewa, S.; et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62, 220-241.
3. Kumar, S.K.; Rajkumar, S.V.; Dispenzieri, A.; Lacy, M.Q.; Hayman, S.R.; Buadi, F.K.; Zeldenrust, S.R.; Dingli, D.; Russell, S.J.; Lust, J.A.; et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111, 2516-2520.
4. Kumar, S.K.; Dispenzieri, A.; Lacy, M.Q.; Gertz, M.A.; Buadi, F.K.; Pandey, S.; Kapoor, P.; Dingli, D.; Hayman, S.R.; Leung, N.; et al. Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia 2014, 28, 1122-1128.
5. Raje, N.; Singhal, S.; Stockerl-Goldstein, K.; Treon, S.P.; Yahalom, J.; Gasparetto, C.; Hernandez-Ilizaliturri, F.; Huff, C.A.; Kassim, A.; Krishnan, A.Y. In NCCN Guidelines Version 2.2014 Multiple Myeloma; National Comprehensive Cancer Network: Fort Washington, PA, USA, 2013.
6. McBride, A.; Ryan, P.Y. Proteasome inhibitors in the treatment of multiple myeloma. Expert. Rev. Anticancer Ther. 2013, 13, 339-358.
7. Moreau, P.; Richardson, P.G.; Cavo, M.; Orlowski, R.Z.; San Miguel, J.F.; Palumbo, A.; Harousseau, J.L. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120, 947-959.
8. Cvek, B. Proteasome inhibitors. Prog. Mol. Biol. Transl. Sci. 2012, 109, 161-226.
9. Grosicki, S.; Barchnicka, A.; Jurczyszyn, A.; Grosicka, A. Bortezomib for the treatment of multiple myeloma. Expert. Rev. Hematol. 2014, 7, 173-185.
10. Adams, J. The proteasome: A suitable antineoplastic target. Nat. Rev. Cancer 2004, 4, 349-360.
11. Jung, T.; Grune, T. Structure of the proteasome. Prog. Mol. Biol. Transl. Sci. 2012, 109, 1-39.
12. Manasanch, E.E.; Korde, N.; Zingone, A.; Tageja, N.; Fernandez de Larrea, C.; Bhutani, M.; Wu, P.; Roschewski, M.; Landgren, O. The proteasome: Mechanisms of biology and markers of activity and response to treatment in multiple myeloma. Leuk Lymphoma 2014, 55, 1707-1714.
13. Kubiczkova, L.; Pour, L.; Sedlarikova, L.; Hajek, R.; Sevcikova, S. Proteasome inhibitors- Molecular basis and current perspectives in multiple myeloma. J. Cell. Mol. Med. 2014, 18, 947-961.
14. Hideshima, T.; Bradner, J.E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S.L.; Anderson, K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 2005, 102, 8567-8572.
15. Obeng, E.A.; Carlson, L.M.; Gutman, D.M.; Harrington, W.J.; Lee, K.P.; Boise, L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107, 4907-4916.
16. Meister, S.; Schubert, U.; Neubert, K.; Herrmann, K.; Burger, R.; Gramatzki, M.; Hahn, S.; Schreiber, S.; Wilhelm, S.; Herrmann, M.; et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67, 1783-1792.
17. Vincenz, L.; Jäger, R.; O'Dwyer, M.; Samali, A. Endoplasmic reticulum stress and the unfolded protein response: Targeting the achilles heel of multiple myeloma. Mol. Cancer Ther. 2013, 12, 831-843.
18. Fuchs, O. Targeting of nf-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc. Hematol. Disord. Drug Targets 2013, 13, 16-34.
19. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K.C. The proteasome inhibitor ps-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61, 3071-3076.
20. LeBlanc, R.; Catley, L.P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C.S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C.S.; Adams, J.; et al. Proteasome inhibitor ps-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000.
21. Ma, M.H.; Yang, H.H.; Parker, K.; Manyak, S.; Friedman, J.M.; Altamirano, C.; Wu, Z.Q.; Borad, M.J.; Frantzen, M.; Roussos, E.; et al. The proteasome inhibitor ps-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 2003, 9, 1136-1144.
22. Gatti, L.; Zuco, V.; Zaffaroni, N.; Perego, P. Drug combinations with proteasome inhibitors in antitumor therapy. Curr. Pharm. Des. 2013, 19, 4094-4114.
23. Lü, S.; Yang, J.; Song, X.; Gong, S.; Zhou, H.; Guo, L.; Song, N.; Bao, X.; Chen, P.; Wang, J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of jurkat T cell lymphoblastic lymphoma/leukemia line. J. Pharmacol. Exp. Ther. 2008, 326, 423-431.
24. Ruud, O.; Niels, E.F.; Yehuda, G.A.; Jacqueline, C.; Ina van, Z.; Celia, R.B.; George, L.S.; Kabir, D.; Katharina, V.; Clara, L.; et al. Molecular basis of bortezomib resistance: Proteasome subunit beta5 (psmb5) gene mutation and overexpression of psmb5 protein. Blood 2008, 112, 2489-2499.
25. Li, Y.; Turner, K.; David, A.; Donald, K. Targeting muc1-c is synergistic with bortezomib in downregulating tigar and inducing ros-mediated myeloma cell death. Blood 2014, 123, 2997-3006.
26. Grant, S. Bortezomib resistance and MUC1 in myeloma. Blood 2014, 123, 2910-2912.
27. Lü, S.; Wang, J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013, 1, 13.
28. Robert, Z.O. Why proteasome inhibitors cannot eradicate multiple myeloma. Cancer Cell 2013, 24, 275-277.
29. Stessman, H.A.; Baughn, L.B.; Sarver, A.; Xia, T.; Deshpande, R.; Mansoor, A.; Walsh, S.A.; Sunderland, J.J.; Dolloff, N.G.; Linden, M.A.; et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol. Cancer Ther. 2013, 12, 1140-1150.
30. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
31. San Miguel, J.F.; Schlag, R.; Khuageva, N.K.; Dimopoulos, M.A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M.T.; Palumbo, A.; Samoilova, O.S.; et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359, 906-917.
32. Hrusovsky, I.; Emmerich, B.; von Rohr, A.; Voegeli, J.; Taverna, C.; Olie, R.A.; Pliskat, H.; Frohn, C.; Hess, G. Bortezomib retreatment in relapsed multiple myeloma-results from a retrospective multicentre survey in germany and switzerland. Oncology 2010, 79, 247-254.
33. Alé, A.; Bruna, J.; Navarro, X.; Udina, E. Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology 2014, 43, 28-35.
34. Argyriou, A.A.; Iconomou, G.; Kalofonos, H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 2008, 112, 1593-1599.
35. Richardson, P.G.; Briemberg, H.; Jagannath, S.; Wen, P.Y.; Barlogie, B.; Berenson, J.; Singhal, S.; Siegel, D.S.; Irwin, D.; Schuster, M.; et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 2006, 24, 3113-3120.
36. Palumbo, A.; Bringhen, S.; Larocca, A.; Rossi, D.; Di Raimondo, F.; Magarotto, V.; Patriarca, F.; Levi, A.; Benevolo, G.; Vincelli, I.D.; et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival. J. Clin. Oncol. 2014, 32, 634-640.
37. Moreau, P.; Pylypenko, H.; Grosicki, S.; Karamanesht, I.; Leleu, X.; Grishunina, M.; Rekhtman, G.; Masliak, Z.; Robak, T.; Shubina, A.; et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol. 2011, 12, 431-440.
38. Hoy, S.M. Subcutaneous bortezomib: In multiple myeloma. Drugs 2013, 73, 45-54.
39. Arnulf, B.; Pylypenko, H.; Grosicki, S.; Karamanesht, I.; Leleu, X.; van de Velde, H.; Feng, H.; Cakana, A.; Deraedt, W.; Moreau, P. Updated survival analysis of a randomized phase iii study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012, 97, 1925-1928.
40. Kapoor, P.; Ramakrishnan, V.; Rajkumar, S.V. Bortezomib combination therapy in multiple myeloma. Semin. Hematol. 2012, 49, 228-242.
41. Wang, L.; Xu, Y.L.; Zhang, X.Q. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: A meta-analysis of 14 randomized controlled trials. Leuk Lymphoma 2014, 55, 1479-1488.
42. Laubach, J.P.; Voorhees, P.M.; Hassoun, H.; Jakubowiak, A.; Lonial, S.; Richardson, P.G. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev. Hematol. 2014, 7, 97-111.
43. Richardson, P.G.; Weller, E.; Lonial, S.; Jakubowiak, A.J.; Jagannath, S.; Raje, N.S.; Avigan, D.E.; Xie, W.; Ghobrial, I.M.; Schlossman, R.L.; et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116, 679-686.
44. Kumar, S.; Flinn, I.; Richardson, P.G.; Hari, P.; Callander, N.; Noga, S.J.; Stewart, A.K.; Turturro, F.; Rifkin, R.; Wolf, J.; et al. Randomized, multicenter, phase 2 study (evolution) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, 119, 4375-4382.
45. Reeder, C.B.; Reece, D.E.; Kukreti, V.; Chen, C.; Trudel, S.; Hentz, J.; Noble, B.; Pirooz, N.A.; Spong, J.E.; Piza, J.G.; et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase ii clinical trial. Leukemia 2009, 23, 1337-1341.
46. Simms-Waldrip, T.; Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A.K.; Fu, C.; Sakamoto, K.M. The aggresome pathway as a target for therapy in hematologic malignancies. Mol. Genet. Metab. 2008, 94, 283-286.
47. Hideshima, T.; Richardson, P.G.; Anderson, K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10, 2034-2042.
48. Nawrocki, S.T.; Carew, J.S.; Pino, M.S.; Highshaw, R.A.; Andtbacka, R.H.I.; Dunner, K.; Pal, A.; Bornmann, W.G.; Chiao, P.J.; Huang, P.; et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66, 3773-3781.
49. Dimopoulos, M.; Siegel, D.S.; Lonial, S.; Qi, J.; Hajek, R.; Facon, T.; Rosinol, L.; Williams, C.; Blacklock, H.; Goldschmidt, H.; et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (vantage 088): A multicentre, randomised, double-blind study. Lancet Oncol. 2013, 14, 1129-1140.
50. Richardson, P.G.; Mitsiades, C.S.; Laubach, J.P.; Hajek, R.; Spicka, I.; Dimopoulos, M.A.; Moreau, P.; Siegel, D.S.; Jagannath, S.; Anderson, K.C. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk. Res. 2013, 37, 829-837.
51. San-Miguel, J.F.; Richardson, P.G.; Günther, A.; Sezer, O.; Siegel, D.; Bladé, J.; LeBlanc, R.; Sutherland, H.; Sopala, M.; Mishra, K.K.; et al. Phase ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J. Clin. Oncol. 2013, 31, 3696-3703.
52. Nawrocki, S.T.; Carew, J.S.; Maclean, K.H.; Courage, J.F.; Huang, P.; Houghton, J.A.; Cleveland, J.L.; Giles, F.J.; McConkey, D.J. Myc regulates aggresome formation, the induction of noxa, and apoptosis in response to the combination of bortezomib and saha. Blood 2008, 112, 2917-2926.
53. Neri, P.; Bahlis, N.J.; Lonial, S. Panobinostat for the treatment of multiple myeloma. Expert Opin. Investig. Drugs 2012, 21, 733-747.
54. Richardson, P.G.; Schlossman, R.L.; Alsina, M.; Weber, D.M.; Coutre, S.E.; Gasparetto, C.; Mukhopadhyay, S.; Ondovik, M.S.; Khan, M.; Paley, C.S.; et al. Panorama 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013, 122, 2331-2337.
55. Thirukkumaran, C.M.; Morris, D.G. Oncolytic virotherapy for multiple myeloma: Past, present, and future. Bone Marrow Res. 2011, 2011, 632948.
56. Kelly, K.R.; Espitia, C.M.; Mahalingam, D.; Oyajobi, B.O.; Coffey, M.; Giles, F.J.; Carew, J.S.; Nawrocki, S.T. Reovirus therapy stimulates endoplasmic reticular stress, noxa induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012, 31, 3023-3038.
57. Sborov, D.W.; Nuovo, G.J.; Stiff, A.; Mace, T.A.; Lesinski, G.B.; Benson, D.M., Jr.; Efebera, Y.A.; Rosko, A.E.; Pichiorri, F.; Grever, M.R.; et al. A phase 1 trial of single agent reolysin in patients with relapsed multiple myeloma. Clin. Cancer Res. 2014, 20, 5946-5955.
58. Kortuem, K.M.; Stewart, A.K. Carfilzomib. Blood 2013, 121, 893-897.
59. Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Jakubowiak, A.J.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M.; et al. A phase 2 study of single-agent carfilzomib (px-171-003-a1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120, 2817-2825.
60. Vij, R.; Siegel, D.S.; Jagannath, S.; Jakubowiak, A.J.; Stewart, A.K.; McDonagh, K.; Bahlis, N.; Belch, A.; Kunkel, L.A.; Wear, S.; et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 2012, 158, 739-748.
61. Jakubowiak, A.J.; Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M.; et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the px-171-003-a1 study. Leukemia 2013, 27, 2351-2356.
62. Siegel, D.; Martin, T.; Nooka, A.; Harvey, R.D.; Vij, R.; Niesvizky, R.; Badros, A.Z.; Jagannath, S.; McCulloch, L.; Rajangam, K.; et al. Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase ii clinical studies. Haematologica 2013, 98, 1753-1761.
63. Badros, A.Z.; Vij, R.; Martin, T.; Zonder, J.A.; Kunkel, L.; Wang, Z.; Lee, S.; Wong, A.F.; Niesvizky, R. Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety. Leukemia 2013, 27, 1707-1714.
64. Wang, M.; Martin, T.; Bensinger, W.; Alsina, M.; Siegel, D.S.; Kavalerchik, E.; Huang, M.; Orlowski, R.Z.; Niesvizky, R. Phase 2 dose-expansion study (px-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013, 122, 3122-3128.
65. Jakubowiak, A.J.; Dytfeld, D.; Griffith, K.A.; Lebovic, D.; Vesole, D.H.; Jagannath, S.; Al-Zoubi, A.; Anderson, T.; Nordgren, B.; Detweiler-Short, K.; et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120, 1801-1809.
66. Jakubowiak, A.J. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview. Cancer Treat. Rev. 2014, 40, 781-790.
67. Zhou, H.J.; Aujay, M.A.; Bennett, M.K.; Dajee, M.; Demo, S.D.; Fang, Y.; Ho, M.N.; Jiang, J.; Kirk, C.J.; Laidig, G.J.; et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (pr-047). J. Med. Chem. 2009, 52, 3028-3038.
68. Savona, M.R.; Berdeja, J.G.; Lee, S.J.; Wong, H.; Lee, J.R.; Gillenwater, H.H.; Siegel, D.S. A phase 1b dose-escalation study of split-dose oprozomib (onx0912) in patients with hematologic malignancies. In Proceedings of 54th ASH Annual Meeting & Exposition, Atlanta, GA, USA, 8-11 December 2012.
69. Kaufman, J.L.; Siegal, D. Haematologica. Clinical Profile of Once-Daily, Modified-Release Oprozomib Tablets in Patients with Hematologic Malignancies: Results of a Phase 1b/2 Trial. In Proceedings of Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association, South San Francisco, CA, USA, 21 May 2013.
70. Ocio, E.M.; Richardson, P.G.; Rajkumar, S.V.; Palumbo, A.; Mateos, M.V.; Orlowski, R.; Kumar, S.; Usmani, S.; Roodman, D.; Niesvizky, R.; et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the international myeloma working group (imwg). Leukemia 2014, 28, 525-542.
71. Allegra, A.; Alonci, A.; Gerace, D.; Russo, S.; Innao, V.; Calabrò, L.; Musolino, C. New orally active proteasome inhibitors in multiple myeloma. Leuk. Res. 2014, 38, 1-9.
72. Metcalf, R.; Scott, L.M.; Daniel, K.G.; Dou, Q.P. Proteasome inhibitor patents (2010-present). Expert. Opin. Ther. Pat. 2014, 24, 369-382.
73. Richardson, P.G.; Delforge, M.; Beksac, M.; Wen, P.; Jongen, J.L.; Sezer, O.; Terpos, E.; Munshi, N.; Palumbo, A.; Rajkumar, S.V.; et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012, 26, 595-608.
74. Dimopoulos, M.A.; Mateos, M.V.; Richardson, P.G.; Schlag, R.; Khuageva, N.K.; Shpilberg, O.; Kropff, M.; Spicka, I.; Palumbo, A.; Wu, K.L.; et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 vista study. Eur. J. Haematol. 2011, 86, 23-31.
75. Han, Y.; Smith, M.T. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front. Pharmacol. 2013, 4, 156.
76. Broyl, A.; Jongen, J.L.M.; Sonneveld, P. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. Semin. Hematol. 2012, 49, 249-257.
77. Broyl, A.; Corthals, S.L.; Jongen, J.L.; van der Holt, B.; Kuiper, R.; de Knegt, Y.; van Duin, M.; el Jarari, L.; Bertsch, U.; Lokhorst, H.M.; et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the hovon-65/gmmg-hd4 trial. Lancet Oncol. 2010, 11, 1057-1065.
78. Arastu-Kapur, S.; Anderl, J.L.; Kraus, M.; Parlati, F.; Shenk, K.D.; Lee, S.J.; Muchamuel, T.; Bennett, M.K.; Driessen, C.; Ball, A.J.; et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin. Cancer Res. 2011, 17, 2734-2743.
79. Kouroukis, C.T.; Baldassarre, F.G.; Haynes, A.E.; Imrie, K.; Reece, D.E.; Cheung, M.C. Bortezomib in multiple myeloma: A practice guideline. Clin. Oncol. (R. Coll. Radiol.) 2014, 26, 110-119.
80. Heider, U.; Rademacher, J.; Kaiser, M.; Kleeberg, L.; von Metzler, I.; Sezer, O. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin. Lymphoma Myeloma Leuk. 2010, 10, 134-137.
81. Palumbo, A.; Rajkumar, S.V.; San Miguel, J.F.; Larocca, A.; Niesvizky, R.; Morgan, G.; Landgren, O.; Hajek, R.; Einsele, H.; Anderson, K.C.; et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J. Clin. Oncol. 2014, 32, 587-600.
82. Lonial, S.; Richardson, P.G.; San Miguel, J.; Sonneveld, P.; Schuster, M.W.; Bladé, J.; Cavenagh, J.; Rajkumar, S.V.; Jakubowiak, A.J.; Esseltine, D.L.; et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br. J. Haematol. 2008, 143, 222-229.
83. Pitzgerald, M.; Fraser, C.; Webb, I.; Schenkein, D.; Esseltine, D.; Weich, N.S. 193normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol. Blood Marrow Transplant. 2003, 9, 121.
84. Lonial, S.; Waller, E.K.; Richardson, P.G.; Jagannath, S.; Orlowski, R.Z.; Giver, C.R.; Jaye, D.L.; Francis, D.; Giusti, S.; Torre, C.; et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106, 3777-3784.
85. Vickrey, E.; Allen, S.; Mehta, J.; Singhal, S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009, 115, 229-232.
86. Jiri, M.; Tomas, P.; Jaroslav, B.; Katerina, L.; Vlastimil, S. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br. J. Haematol. 2012, 159, 111-113.
87. Uy, G.L.; Peles, S.; Fisher, N.M.; Tomasson, M.H.; DiPersio, J.F.; Vij, R. Bortezomib prior to autologous transplant in multiple myeloma: Effects on mobilization, engraftment, and markers of immune function. Biol. Blood Marrow Transplant. 2006, 12, 116.
88. Vij, R.; Wang, M.; Kaufman, J.L.; Lonial, S.; Jakubowiak, A.J.; Stewart, A.K.; Kukreti, V.; Jagannath, S.; McDonagh, K.T.; Alsina, M.; et al. An open-label, single-arm, phase 2 (px-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012, 119, 5661-5670.
89. Kuhn, D.J.; Hunsucker, S.A.; Chen, Q.; Voorhees, P.M.; Orlowski, M.; Orlowski, R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113, 4667-4676.
90. Huber, E.M.; Groll, M. Inhibitors for the immuno- and constitutive proteasome: Current and future trends in drug development. Angew. Chem. Int. Ed. Engl. 2012, 51, 8708-8720.
91. Miller, Z.; Ao, L.; Kim, K.B.; Lee, W. Inhibitors of the immunoproteasome: Current status and future directions. Curr. Pharm. Des. 2013, 19, 4140-4151.
92. Kuhn, D.J.; Orlowski, R.Z. The immunoproteasome as a target in hematologic malignancies. Semin. Hematol. 2012, 49, 258-262.
93. Agyin, J.K.; Santhamma, B.; Roy, S.S. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma. Bioorg. Med. Chem. Lett. 2013, 23, 6455-6458.
94. Ludwig, H.; Kasparu, H.; Leitgeb, C.; Rauch, E.; Linkesch, W.; Zojer, N.; Greil, R.; Seebacher, A.; Pour, L.; Weißmann, A.; et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014, 123, 985-991.
95. Romano, A.; Chiarenza, A.; Conticello, C.; Cavalli, M.; Vetro, C.; Di Raimondo, C.; Cunsolo, R.; Palumbo, G.A.; Di Raimondo, F. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. Eur. J. Haematol. 2014, 93, 207-213.